DK4455141T3 - Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes - Google Patents

Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes

Info

Publication number
DK4455141T3
DK4455141T3 DK22910193.6T DK22910193T DK4455141T3 DK 4455141 T3 DK4455141 T3 DK 4455141T3 DK 22910193 T DK22910193 T DK 22910193T DK 4455141 T3 DK4455141 T3 DK 4455141T3
Authority
DK
Denmark
Prior art keywords
glp
pharmaceutically acceptable
acceptable salt
crystalline form
receptor agonist
Prior art date
Application number
DK22910193.6T
Other languages
Danish (da)
English (en)
Inventor
Weidong Lu
Gujun Xu
Junran Yang
Qiyun Shao
Zhenxing Du
Jun Feng
Feng He
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of DK4455141T3 publication Critical patent/DK4455141T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK22910193.6T 2021-12-23 2022-12-23 Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes DK4455141T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111584574 2021-12-23
PCT/CN2022/141418 WO2023116882A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
DK4455141T3 true DK4455141T3 (da) 2026-04-27

Family

ID=86901360

Family Applications (1)

Application Number Title Priority Date Filing Date
DK22910193.6T DK4455141T3 (da) 2021-12-23 2022-12-23 Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes

Country Status (11)

Country Link
US (1) US20250049777A1 (https=)
EP (2) EP4455141B1 (https=)
JP (1) JP2024547113A (https=)
KR (1) KR20240125003A (https=)
CN (1) CN118434730A (https=)
AU (1) AU2022418658A1 (https=)
CA (1) CA3241670A1 (https=)
DK (1) DK4455141T3 (https=)
MX (1) MX2024007906A (https=)
TW (1) TW202328114A (https=)
WO (1) WO2023116882A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025148954A1 (zh) * 2024-01-09 2025-07-17 山东盛迪医药有限公司 一种glp-1r激动剂药物组合物及其应用
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
CN115697338B (zh) * 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CA3188891A1 (en) * 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
TW202328114A (zh) 2023-07-16
EP4732838A2 (en) 2026-04-29
MX2024007906A (es) 2024-07-10
AU2022418658A1 (en) 2024-07-11
CN118434730A (zh) 2024-08-02
EP4455141B1 (en) 2026-03-25
EP4455141A1 (en) 2024-10-30
EP4455141A4 (en) 2025-04-09
CA3241670A1 (en) 2023-06-29
JP2024547113A (ja) 2024-12-26
US20250049777A1 (en) 2025-02-13
WO2023116882A1 (zh) 2023-06-29
KR20240125003A (ko) 2024-08-19

Similar Documents

Publication Publication Date Title
DK4455141T3 (da) Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes
DK4058445T3 (da) Glp-1-receptoragonist og anvendelse deraf
EP4069686A4 (en) GPP-1 RECEPTOR AGONISTS
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
CL2022002466A1 (es) Agonista del receptor de glp-1, composición farmacéutica, y método de preparación
DK3989972T3 (da) Glucagon-lignende peptid-1-receptor-agonister
MA54862A (fr) Procédé de préparation d'un agoniste double gip/glp1
EP4130005A4 (en) CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
DK4076652T3 (da) Farmaceutisk acceptabelt atrasentansalt til anvendelse i en fremgangsmåde til behandling af iga-nefropati
IL299707A (en) Co-agonists for GLP-1 and GIP receptors
EP4141008A4 (en) PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR
EP3700550A4 (en) LONG-ACTING CO-AGONISTS OF GLUCAGON AND GLP-1 RECEPTORS
IL291681B1 (en) Glucagon/glp– – medical use of a trigonal receptor agonist or its conjugate for liver disease /gip
IL280159A (en) Method of using a gip/glp1 co-agonist for diabetes
IL299701A (en) GLP-1 and GIP receptor co-agonists suitable for oral administration
EP4317179A4 (en) GIP AND GLP-1 DUAL RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION AND USE
SG11202102586RA (en) Crystalline forms of a farnesoid x receptor agonist
EP4442700A4 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
IL304828A (en) Glucagon-like peptide-1 receptor antagonists
PL4289824T3 (pl) Związek uracylowy zawierający fragment karboksylanowy i sposób jego przygotowania, kompozycja chwastobójcza i zastosowanie
JOP20200128A1 (ar) صور متعددة وصور صلبة من مركب بيريميدين يل أمينو-بيرازول، وطرق إنتاجها
LT3456340T (lt) Glp-1 receptoriaus antagonistas, skirtas įgimto hiperinsulinizmo gydymui
IL325358A (en) Heterocyclic glp-1 agonists
EP4201935A4 (en) Crystal of compound x7 hydrochloride, preparation method therefor and use thereof
DK4482579T3 (da) Forbindelser og sammensætninger til behandling af tilstande forbundet med lpa-receptoraktivitet